Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oligomannate

- PMLiVE

Funding boost for late-stage tau-based Alzheimer’s research

Singapore company TauRx receives $112m investment to take LMTX treatment into phase III

Charles River Laboratories acquires Chinese research company

Pays $27m for Beijing-based Vital River

Market access opportunities in China

Pope Woodhead highlights the key steps to accessing the high-value therapeutics market in China

- PMLiVE

AstraZeneca signs IBS collaboration with Ironwood in China

Deal will also see Ironwood’s US sales force promote Nexium for gastroesophageal reflux disease

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

China flag thumb

China slashes drug prices as healthcare reforms announced

Raft of measures to cut healthcare costs include 17 per cent price reduction for cancer drugs

- PMLiVE

J&J to launch ‘innovation centres’ in US, UK and China

Will target local life sciences partnerships in early-stage innovation

- PMLiVE

Postcards from China

Part two: The value of innovative medical education in China

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

PRA opens Beijing office to expand Chinese operations

New office adds to the CRO's existing base in Shanghai

China to be second largest online ad spender by 2014

China set to be the second largest online ad spender by 2014, with the whole of Asia-Pacific predicted to overtake Western Europe by 2013 and overall ad spend in China...

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links